Following this week’s oral argument at the U.S. Court of Appeals for the
Federal Circuit, there has been a surge of interest in the long-running
CRISPR patent dispute between the Regents of the University of California
(with collaborators the University of Vienna and Emmanuelle Charpentier) and
the Broad Institute (with collaborators Harvard and MIT). This article
summarizes the broader patent war between those two sides and addresses its
potential implications for others seeking to use CRISPR-based technologies.